Group 1 - The report from CMB International maintains a "Buy" rating for NIO-SW (09866), indicating a potential short-term rebound in stock price due to marginal improvements, particularly in sales recovery [1] - Despite a 50% rebound from lower levels, NIO's price-to-sales ratio for 2025 is only 0.85 times, which is still lower than the 1-2 times valuation of its peers in the new energy vehicle sector, suggesting further upside potential for the stock [1] Group 2 - The launch of the Lido L90 model has a starting price of 265,800 RMB for the Pro version, with the Max and Ultra versions priced at 279,800 RMB and 299,800 RMB respectively; the seven-seat model starts at 271,800 RMB [2] - The official pricing is approximately 14,100 RMB lower than the pre-sale price announced on July 10, indicating a strategic pricing adjustment [2] - The L90 model includes high-end features such as an 85kWh battery, L2-level intelligent driving assistance system, and Orin-X chip, with promotional offers to encourage purchases [2] - The management's pricing strategy reflects a strong commitment to achieving sales targets, with expectations of monthly sales exceeding the market forecast of 5,000 units [2] - The success of the L90 model is anticipated to pave the way for the upcoming L80 model, contributing to a turnaround in NIO's sales performance [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 交銀國際控股有限公司 | | | 呈交日期: | 2025年8月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 第 2 頁 共 10 頁 v 1.1.1 FF301 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） 不適用 第 3 頁 共 10 頁 v 1.1.1 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03329 | 說明 | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | ...

Core Viewpoint - The Federal Reserve decided to maintain the federal funds rate target range at 4.25% to 4.5% during the July FOMC meeting, marking the fifth consecutive meeting without a rate cut, aligning with market expectations [1] Group 1: Federal Reserve Decisions - The Fed's decision to pause rate cuts reflects a cautious approach, as the impact of tariffs has a lagging effect that has not yet fully manifested [1] - The probability of a rate cut in September decreased from approximately 65% before the meeting to around 45% afterward, indicating a shift in market sentiment [1] - The Fed is expected to wait for two complete rounds of employment and inflation data before making further decisions, particularly regarding the transmission of commodity price pressures [1] Group 2: Market Implications - The outlook for rate cuts in 2023 has moderated, with expectations for 1-2 rate cuts by the end of 2025, and the first potential cut could occur in the fourth quarter [1] - Concerns about dollar credit risk and capital market performance may limit political pressures on the Fed, including potential calls for tariff adjustments or dismissing Fed Chair Powell [1]

Core Viewpoint - The report from CMB International maintains a target price of HKD 46 for New Oriental-S (09901) and a "Buy" rating, despite a downward adjustment in revenue and operating profit forecasts for the fiscal years 2026 and 2027 [1] Revenue and Profit Forecasts - The company has lowered its revenue forecast by approximately 3% for the fiscal years 2026 and 2027, expecting revenue growth rates of 10% and 14% respectively [1] - Operating profit is expected to decrease by about 17%, with operating profit margins projected at 10.2% and 10.5%, showing a slight increase compared to the fiscal year 2025 [1] Business Segment Performance - CMB International remains optimistic about the demand and growth prospects for K12 education and training-related businesses [1] - The first quarter guidance was below expectations mainly due to seasonal factors, but growth rates are expected to recover in the second to fourth quarters [1] Valuation Methodology - The valuation method has been adjusted to SOTP (Sum of the Parts), assigning a price-to-earnings ratio of 15 times for K12 business and 8 times for study abroad business for the fiscal year 2026, corresponding to profit growth rates of +22% and -10% respectively [1] Quarterly Performance - In the fourth quarter of fiscal year 2025, revenue increased by 9.4% year-on-year, surpassing the expectations of CMB International and other institutions, which were 2% and 5% respectively [1] - Excluding Dongfang Zhenxuan (01797), education and cultural tourism revenue grew by 19% year-on-year, with an education operating profit margin of 6.5%, an increase of 410 basis points compared to the same period last year, attributed to effective cost reduction and efficiency improvement measures [1] Management Guidance - The management has indicated that the group’s revenue is expected to increase by 5-10% for the fiscal year 2026, compared to the market expectation of 12% [1] - The main adjustment is a downward revision of the growth forecast for overseas-related business to a decline of 5%, while the growth rate for K12-related business remains in line with market expectations at 19% [1] - The company is accelerating cost optimization efforts, aiming to achieve stable or slightly increased operating profit margins for the year [1]

Core Viewpoint - The report from CMB International maintains a target price of HKD 46 for New Oriental-S (09901) and a "Buy" rating, while adjusting revenue and operating profit forecasts for the fiscal years 2026 and 2027 downward by approximately 3% and 17% respectively [1] Group 1: Financial Projections - Revenue growth is expected at 10% and 14% for fiscal years 2026 and 2027 respectively, with an operating profit margin projected at 10.2% and 10.5%, showing a slight increase compared to fiscal year 2025 [1] - The fourth quarter of fiscal year 2025 saw a revenue increase of 9.4% year-on-year, surpassing the expectations of CMB International and other institutions, which were 2% and 5% respectively [1] - Excluding Dongfang Zhenxuan (01797), education and cultural tourism revenue increased by 19% year-on-year, with an education operating profit margin of 6.5%, up 410 basis points from the same period last year due to effective cost reduction and efficiency improvement measures [1] Group 2: Business Segments and Market Outlook - The guidance for the first quarter was below expectations primarily due to seasonal factors, but growth is expected to recover in the second to fourth quarters [1] - The management's guidance for fiscal year 2026 indicates a group revenue increase of 5-10%, compared to the market expectation of 12%, with the main adjustment being a downward revision of the growth forecast for overseas-related business to a decline of 5% [1] - The growth rate for K12-related business is maintained at the market expectation of 19% [1] Group 3: Valuation Methodology - CMB International has adjusted its valuation method to SOTP, assigning a price-to-earnings ratio of 15 times for K12 business and 8 times for study abroad business for fiscal year 2026, corresponding to profit growth rates of +22% and -10% respectively [1] - The company is accelerating cost optimization efforts, aiming to achieve stable or slightly increased operating profit margins for the entire year [1]

该行预计平安2025上半年归母营运利润同比增长5%，寿险健康险、财险和银行这三大核心业务板块仍 贡献稳健营运利润，非核心板块盈利改善。 该行预计第二季度归母净利润同比增长13.5%。预计财险承保端显著改善，投资端保持稳健，财险水净 利润同比增长6%。预计上半年新业务价值同比增长36%，价值率同比保持提升态势。 瑞财经王敏近日，交银国际发布研报称，基于2025年1.2倍市净率，将中国平安(02318)目标价从60港元 上调22%至73港元，维持"买入"评级。 该行上调盈利预测，预计2025年营运利润同比增长7%，归母净利润同比增长5%。该行预计公司2025-27 年ROE有望保持在13%以上，目前公司2025年市净率低于1倍，股息率为5%左右，估值仍具吸引力。 相关公司：中国平安sh601318,交银国际hk03329 本文源自：智通财经网 ...

Core Viewpoint - The stock of China International Capital Corporation (CICC) has shown significant growth, with a cumulative increase of 110.71% over the past month and 87.3% year-to-date, outperforming the Hang Seng Index by 25.27% [2] Group 1: Financial Performance - As of December 31, 2024, CICC reported total operating revenue of 359 million yuan, a year-on-year decrease of 36.8% [2] - The company recorded a net loss attributable to shareholders of 1.14 billion yuan, an increase of 16.21% year-on-year [2] - The asset-liability ratio stands at 93.92% [2] Group 2: Market Position and Valuation - Currently, there are no institutional investment ratings for CICC [3] - The average price-to-earnings (P/E) ratio for the financial industry (TTM) is 16.25 times, with CICC's P/E ratio at -1.31 times, ranking 153rd in the industry [3] - Other financial companies have P/E ratios ranging from 2.63 times to 4.8 times [3] Group 3: Company Overview - CICC, established in 1998, is one of the earliest licensed securities firms in Hong Kong with a Chinese background [4] - The company has evolved into a large securities firm specializing in brokerage, margin financing, corporate financing, underwriting, investment, loans, asset management, and advisory services [4][5] - CICC aims to leverage cross-border business opportunities and provide comprehensive financial services to create greater value for clients and shareholders [4]

本报讯 （记者李雯珊 见习记者张美娜）7月18日，以"新质驱动·未来领航"为主题的2025中国（深圳） 独角兽企业大会在深圳盛大开幕。深圳市政府副秘书长罗育德出席，深圳市工业和信息化局党组书记、 局长黄强、中国企业联合会驻会副会长李冰、交通银行深圳分行党委委员、副行长谢磊先后致辞。北京 市长城企业战略研究所（以下简称"长城策略咨询"）董事长武文生发布《GEI中国独角兽企业研究报告 2025》、深圳市创新投资集团有限公司总裁刘苏华发布《深圳市独角兽企业及瞪羚企业研究报告 2025》。深圳市工业和信息化局党组成员、市中小企业服务局局长吕哲、交通银行（香港）有限公司副 行政总裁杨浩、深圳市投资促进局副局长刘振强、市贸促会党组成员、副主任汤进、深圳市报业集团社 委会委员、副总编辑肖意、深圳市福田区副区长余枫等出席会议。 大会上，深圳市工业和信息化局党组书记、局长黄强表示："深圳作为全国工业第一城、全球十大金融 中心，深圳市委、市政府高度重视独角兽企业培育工作，今年3月份出台《深圳市有力有效支持发展瞪 羚企业、独角兽企业行动计划（2025-2027年）》，构建从发掘培育到金融赋能的全链条支持体系。此 外，深圳还拥有深交 ...

Group 1 - The Hang Seng Index closed down by 0.08% while the Hang Seng Tech Index increased by 0.56% [1] - The Hong Kong Tech ETF (159751) rose by 1.22%, whereas the Hang Seng Hong Kong Stock Connect ETF (159318) fell by 0.30% [1] - Pop Mart experienced a decline of 0.87% after a recovery attempt [1] Group 2 - China International Capital Corporation (CICC) saw a significant drop of over 11% [1]

Group 1 - The core viewpoint of the news is that the Hong Kong stock market, particularly the healthcare sector, is experiencing a strong rally driven by the revaluation of innovative drug companies, with significant increases in stock prices and ETF performance [1][2]. - The CSI Hong Kong Innovative Drug Index rose by 4.23%, with notable gains from companies such as Fudan Zhangjiang (over 18% increase), Lepu Biopharma-B (over 10% increase), and Kangfang Biotech (over 9% increase) [1]. - The Hong Kong Innovative Drug 50 ETF (513780) saw a 3.57% increase, with a trading volume exceeding 200 million yuan within the first half hour of trading [1]. Group 2 - According to Jiao Yin International, the current innovative drug market in Hong Kong is driven by value re-evaluation, with attractive valuations compared to U.S. counterparts, as leading innovative drug companies have a forward 12-month price-to-sales ratio around 3 times, lower than the U.S. average of 4 times [2]. - Donghai Securities noted that the domestic innovative drug sector has seen increased activity this year, with high-value business development transactions and rising R&D investments, indicating a potential systematic recovery in the CXO and upstream life sciences sectors [2]. - Investment opportunities are suggested in various sub-sectors including CXO, innovative drugs, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [2].